{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02054208",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MP-CR-010"
      },
      "Organization": {
        "OrgFullName": "Medipost Co Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease",
      "OfficialTitle": "A Double-blind, Single-center, Phase 1/2a Clinical Trial to Evaluate the Safety and Exploratory Efficacy of Intraventricular Administrations of NEUROSTEM® Versus Placebo Via an Ommaya Reservoir in Patients With Alzheimer's Disease"
    },
    "StatusModule": {
      "StatusVerifiedDate": "August 2018",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2014",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2019",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "January 29, 2014",
      "StudyFirstSubmitQCDate": "February 3, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 4, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "August 26, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "August 28, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Medipost Co Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity (DLT), and exploratory efficacy of three repeated intraventricular administrations of NEUROSTEM® (human umbilical cord blood-derived mesenchymal stem cells) versus placebo via an Ommaya reservoir at 4 week intervals in patients with Alzheimer's disease.",
      "DetailedDescription": "The study is divided into the 2 stages: dose-escalation in stage 1 and randomized and multiple-dose cohort parallel design in stage 2.The target population for enrollment in this study is patients with mild to moderate Alzheimer's disease."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Alzheimer's Disease"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "human umbilical cord blood derived mesenchymal stem cells",
          "stem cells",
          "alzheimer's disease",
          "cognitive ability",
          "mesenchymal stem cells",
          "cord blood"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "Stage 1: 9 subjects (3 subjects for low dose and 6 subjects for high dose) Stage 2: 36 subjects ( 24 subjects for high dose and 12 subjects for placebo) A total of 45 subjects to be enrolled",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "46",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "NEUROSTEM (hUCB-MSCs)- low dose",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: human umbilical cord blood derived mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "NEUROSTEM (hUCB-MSCs) - high dose",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: human umbilical cord blood derived mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "normal saline 2mL, doses separated by 4 weeks for a total of 3 doses",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Normal saline 2mL"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "human umbilical cord blood derived mesenchymal stem cells",
            "InterventionDescription": "Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals\n\nHigh dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "NEUROSTEM (hUCB-MSCs) - high dose",
                "NEUROSTEM (hUCB-MSCs)- low dose"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "NEUROSTEM"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Normal saline 2mL",
            "InterventionDescription": "Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of subjects with adverse events",
            "PrimaryOutcomeDescription": "Number of subjects with adverse event, number of subjects with normal range of vital signs, mixed lymphocyte reaction result, and laboratory examination result",
            "PrimaryOutcomeTimeFrame": "24 weeks after the first dose"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change from the baseline in ADAS-Cog",
            "SecondaryOutcomeDescription": "Alzheimer's Disease assessment Scale-Cognitive Subscale",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change from the baseline in S-IADL",
            "SecondaryOutcomeDescription": "Seoul Instrumental Activities of Daily Living",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change from the baseline in K-MMSE",
            "SecondaryOutcomeDescription": "Mini Mental State Exmination Korean version",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change from the baseline in CGA-NPI",
            "SecondaryOutcomeDescription": "Caregiver-administered Neuropsychiatric Inventory",
            "SecondaryOutcomeTimeFrame": "24 weeks from the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "ADAS-Cog Response Rate",
            "SecondaryOutcomeDescription": "ADAS-cog response is defined as no worsening (no change or improvement on ADAS-cog score) of the ADAS-cog score at 24 weeks after the first administration compared to the baseline",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change in CDR-SOB",
            "SecondaryOutcomeDescription": "Clinical Dementia Rating-Sum of Box",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Florbetaben-PET",
            "SecondaryOutcomeDescription": "Florbetaben - Pittsburgh Compound B-positron emission tomography",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)",
            "SecondaryOutcomeDescription": "fluorodeoxyglucose positron emission tomography",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change in CIBIC-plus",
            "SecondaryOutcomeDescription": "The Clinician's Interview Based Impression of Change-plus",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change from baseline in MRI (DTI mapping)",
            "SecondaryOutcomeDescription": "MRI Analysis",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change from the baseline in CSF biomarkers",
            "SecondaryOutcomeDescription": "biomakrer analysis",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "1 stage Inclusion Criteria:\n\nKorean male or female at 50 -85 years of age\nDiagnosis of Probable Alzheimer type according to NINCDS-ADRDA criteria at Visit 1 (Screening)\nKorea Mini-Mental State Examination (KMMSE) score of 18 - 26 at Visit 1 (Screening)\nPositive for Amyloid on PIB-PET or Florbetaben PET\nA subject who is informed of the clinical trial and signs a consent form (if unable to sign, a consent from a legally acceptable representative is required)\n\n2 stage Inclusion Criteria:\n\nKorean male or female at 50 -85 years of age\nDiagnosis of Probable Alzheimer type or mild cognitive impairment due to Alzheimer's disease (stage A) according to NIA-AA criteria at Visit 1(Screening)\nKorea Mini-Mental State Examination (KMMSE) score of over 18 at Visit 1 (Screening)\nPositive for Amyloid on Florbetaben PET\nA subject with neurodegeneration (mild atrophy of the brain) as confirmed by MRI\nA subject who is informed of the clinical trial and signs a consent form (if unable to sign, a consent from a legally acceptable representative is required)\n\nExclusion Criteria:\n\nConcurrent mental disorder (such as schizophrenia, depression, bi-polar diseases or others) aside from dementia\nConcurrent dementia as a result of other neurodegenerative disorders (due to infectious disease of the central nervous system such as HIV, syphilis), head injury, Creutzfeld-Jacob disease, Pick's disease, Huntington's disease, or Parkinson's disease\nDiagnosis of severe white matter hyperintensitivity (WMH) according to CREDOS (Clinical REsearch Center for Dementia of South Korea), which is defined as ≥ 25mm of the deep white matter and ≥ 10mm of the periventricular capping/banding in lengths\nHistory of stroke within 3 months prior to study enrollment\nSevere liver disorder (equivalent to double the normal values of ALT and AST) at Visit 1\nSevere kidney disorder (serum creatinine ≥1.5mg/dL) at Visit 1\nPregnant or lactating females\n\nAbnormal Laboratory findings at Visit 1\n\nHemoglobin < 9.5 g/dL for male and <9.0 g/dL for female\nTotal WBC Count < 3000/mm3\nTotal Bilirubin >= 3 mg/dL\nSuspected active lung disease based on chest X-ray at Visit 1\nWoman of childbearing age who refuses to practice medically acceptable contraceptive method (post menopausal patient with no menstruation for at least 12 months is considered as infertile)\nHistory of screening failure for the clinical trial of NEUROSTEM® in the past 6 months\nParticipation in another clinical trial in the past 3 months prior to the beginning (Week 0) of this clinical trial\nBleeding disorder (abnormal blood coagulation test result (i.e. platelet count of < 150,000/mm3, PT ≥ 1.5 INR, or aPTT ≥ 1.5 x control anti-coagulant or anti-platelet, without anticoagulant or anti-platelet therapy)\nDiagnosis of cancer (of any body system, including brain tumor)\nSubstance/alcohol abuse\nContraindicated for any of the tests performed during the clinical trial period (for example, MRI, CT, PET)\nA subject in whom Ommaya reservoir insertion is considered difficult\nWhom the principal investigator considers inappropriate for participation in the study due to any reasons other than those listed above",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "50 Years",
      "MaximumAge": "85 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Wonil Oh, MD, PhD",
            "OverallOfficialAffiliation": "Medipost Co Ltd.",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Samsung Medical Center",
            "LocationCity": "Seoul",
            "LocationCountry": "Korea, Republic of"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "34521461",
            "ReferenceType": "derived",
            "ReferenceCitation": "Kim HJ, Cho KR, Jang H, Lee NK, Jung YH, Kim JP, Lee JI, Chang JW, Park S, Kim ST, Moon SW, Seo SW, Choi SJ, Na DL. Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial. Alzheimers Res Ther. 2021 Sep 14;13(1):154. doi: 10.1186/s13195-021-00897-2."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "first-in-man study of NEUROSTEM",
            "SeeAlsoLinkURL": "http://www.clinicaltrials.gov/ct2/show/NCT01297218?term=neurostem&rank=2"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000000544",
            "ConditionMeshTerm": "Alzheimer Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000003704",
            "ConditionAncestorTerm": "Dementia"
          },
          {
            "ConditionAncestorId": "D000001927",
            "ConditionAncestorTerm": "Brain Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000024801",
            "ConditionAncestorTerm": "Tauopathies"
          },
          {
            "ConditionAncestorId": "D000019636",
            "ConditionAncestorTerm": "Neurodegenerative Diseases"
          },
          {
            "ConditionAncestorId": "D000019965",
            "ConditionAncestorTerm": "Neurocognitive Disorders"
          },
          {
            "ConditionAncestorId": "D000001523",
            "ConditionAncestorTerm": "Mental Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3037",
            "ConditionBrowseLeafName": "Alzheimer Disease",
            "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6056",
            "ConditionBrowseLeafName": "Dementia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4356",
            "ConditionBrowseLeafName": "Brain Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22155",
            "ConditionBrowseLeafName": "Tauopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20711",
            "ConditionBrowseLeafName": "Neurodegenerative Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20989",
            "ConditionBrowseLeafName": "Neurocognitive Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3967",
            "ConditionBrowseLeafName": "Mental Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13625",
            "ConditionBrowseLeafName": "Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2192",
            "ConditionBrowseLeafName": "Familial Alzheimer Disease",
            "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXM",
            "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}